Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paltusotine in Acromegaly (PATHFNDR-1)
NCT04837040Phase 3Terminated
- Sponsor
- Crinetics Pharmaceuticals
- Start
- May 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of paltusotine in acromegaly, sponsored by Crinetics Pharmaceuticals. Started May 2021; status: terminated.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT04837040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837040.